Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review

Montero‐Vílchez, Trinidad; Pozo-Román, T; Sánchez-Velicia, L.; Vega-Gutiérrez, J; Arias‐Santiago, Salvador; Molina-Leyva, Alejandro

doi:10.1080/09546634.2020.1755008

Cited by 35 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, long‐term clinical responses range only from 52 to 57% 2 . Tildrakizumab (anti‐IL‐23), 3 guselkumab (anti‐IL‐23) 4 and ustekinumab (anti‐IL‐12/23) 5 have been successfully used in HS.…”

Section: Patient 1 Patientmentioning

confidence: 99%

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

et al. 2021

View full text Add to dashboard Cite

DEAR EDITOR, Hidradenitis suppurativa (HS) is a relapsing inflammatory skin disease. The cytokines interleukin (IL)-1b, IL-12, IL-23, IL-17 and tumour necrosis factor (TNF)-a are involved in the inflammatory process. 1 The only approved drug for the treatment of moderate-to-severe cases is adalimumab (a TNF-a inhibitor). However, long-term clinical responses range only from 52 to 57%. 2 Tildrakizumab (anti-IL-23), 3 guselkumab (anti-IL-23) 4 and ustekinumab (anti-IL-12/23) 5 have been successfully used in HS.Risankizumab is a humanized IgG1 monoclonal antibody selective to IL-23. It is currently approved for the treatment of moderate-to-severe plaque psoriasis in adults. 6 We describe two patients with severe Hurley Stage III HS, successfully treated with risankizumab:Patient 1 was a 39-year-old woman, a nonsmoker with a body mass index (BMI, kg m -2 ) of 28Á9. Her medical history included depression and multiple sclerosis (MS). Her mother and grandfather have been treated for HS. Historically, she was treated with systemic azithromycin, doxycycline, clindamycin, rifampicin, isotretinoin and, lastly, adalimumab (40 mg per week subcutaneously). Three months after starting adalimumab, she achieved a Hidradenitis Suppurativa Clinical Response (HiSCR). Loss of response (LoR) was observed after 20 months and consequently adalimumab was discontinued

show abstract

Section: Patient 1 Patientmentioning

confidence: 99%

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a Phase II open-label study involving 17 patients, patients showed moderate-to-marked improvement achieving HiSCR in almost 40% of cases [ 136 ]. Several cases series reported positive outcomes using ustekinumab in moderate-to-severe HS patients [ 136 , 137 , 138 ].…”

Section: Resultsmentioning

confidence: 99%

Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa

Duca

Morelli

Bennardo

et al. 2020

IJMS

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting areas with a high density of apocrine glands and characterized by subcutaneous nodules that may evolve into fistulas with pus secretion. Methods: The aim of this review is to investigate all current knowledge on cytokine regulation in the pathogenesis of HS. A systematic literature research using the words “cytokine”, “interleukin”, “pathway”, and “hidradenitis suppurativa” was performed in PubMed/Medline and Scopus/Embase databases. A search of the clinicaltrials.gov website for interventional recruiting and completed trials including the term “hidradenitis suppurativa” was also performed up to August 2020. We will discuss the pathogenetic role of various cytokines in HS and potential therapeutic targets for this debilitating disease. Results: The pathophysiology underlying this complex condition has not been clearly defined. An upregulation of various cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-17, IL-23, and other molecules seems to be related to this inflammatory condition. Various cells, such as lymphocytes T Helper 1 and 17 and keratinocytes seem to be involved in the genesis of this condition. Conclusions: Several future studies and clinical trials are necessary in order to have new knowledge about HS and to properly treat this complex condition.

show abstract

“…Despite of the lack of randomized clinical trials that support the efficacy and safety of ustekinumab in HS, some case reports and case series have been published in the literature [3][4][5][6][7][8][9] ; to the best of our knowledge, 49 cases have been published to date. The dosage used was variable, but most of the patients received the psoriasis dosage regimen.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Sánchez‐Martínez

Ruiz

Moneva-Leniz

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, systemic, inflammatory dermatosis which lacks curative treatment. Its management can be challenging, thus a variety of therapies are commonly used, such as antibiotics, anti-inflammatory drugs, retinoids, surgery and biological treatments. Adalimumab is the only approved biological therapy for HS, while secukinumab, risankizumab or guselkumab are currently under investigation with ongoing trials for HS. 1,2 To our knowledge, there are currently no clinical trials being conducted to assess the efficacy of ustekinumab in HS. The present study provides some extra evidence about the effectiveness and safety of ustekinumab in HS.

show abstract

Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review

Cited by 35 publications

References 16 publications

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha

Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa

Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Contact Info

Product

Resources

About